Evidence map›Paper›PMID 41813706›Full record

ArticleScientific reports2026

Clinically interpretable nomogram combining body composition and clinicopathological features for one year survival prediction in advanced solid tumors.

Giulia Bruschi, Francesco Paoloni, Federica Pecci, Elisabetta Tola, Valeria Cognigni, Tommaso Galassi, Alessandra Borgheresi, Luca Cantini, Luca Santamaria, Mariangela Gualtieri and 18 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Giulia Bruschi *Department of Information Engineering, Marche Polytechnic University, Ancona, Italy.
Francesco Paoloni *Marche Polytechnic University, Clinical Oncology, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy.
Federica Pecci *Marche Polytechnic University, Clinical Oncology, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy. peccifede91@gmail.com.
Elisabetta TolaDepartment of Clinical, Special, and Dental Sciences (DISCO), Department of Radiological Sciences, Marche Polytechnic University, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy.
Valeria CognigniMarche Polytechnic University, Clinical Oncology, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy.
Tommaso GalassiMarche Polytechnic University, Clinical Oncology, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy.
Alessandra BorgheresiDepartment of Clinical, Special, and Dental Sciences (DISCO), Department of Radiological Sciences, Marche Polytechnic University, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy.
Luca CantiniFortrea Inc., Durham, NC, USA.
Luca SantamariaMarche Polytechnic University, Clinical Oncology, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy.
Mariangela GualtieriMarche Polytechnic University, Clinical Oncology, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy.
Valentina LunertiMarche Polytechnic University, Clinical Oncology, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy.
Natalia ChiodiDepartment of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy.
Veronica AgostinelliMarche Polytechnic University, Clinical Oncology, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy.
Marzia Di Pietro PaoloMarche Polytechnic University, Clinical Oncology, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy.
Agnese SbrolliniDepartment of Information Engineering, Marche Polytechnic University, Ancona, Italy.
Andrea AgostiniDepartment of Clinical, Special, and Dental Sciences (DISCO), Department of Radiological Sciences, Marche Polytechnic University, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy.
Giulia MentrastiMarche Polytechnic University, Clinical Oncology, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy.
Salvatore FicarraDivision of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
Giulia MazzaschiDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Alessandro ParisiMarche Polytechnic University, Clinical Oncology, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy.
Riccardo GiampieriMarche Polytechnic University, Clinical Oncology, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy.
Kamal S SainiFortrea Inc., Durham, NC, USA.
Sebastiano ButiDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Marcello TiseoDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Arianna VigniniDepartment of Clinical, Special, and Dental Sciences (DISCO), Department of Clinical Sciences, Section of Biochemistry, Biology and Physics, Marche Polytechnic University, Ancona, Italy.
Andrea GiovagnoniDepartment of Clinical, Special, and Dental Sciences (DISCO), Department of Radiological Sciences, Marche Polytechnic University, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy.
Laura Burattini *Department of Information Engineering, Marche Polytechnic University, Ancona, Italy.
Rossana Berardi *Marche Polytechnic University, Clinical Oncology, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy. r.berardi@staff.univpm.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) have improved outcomes for patients with solid tumors, but reliable predictors of overall survival (OS) are limited. This retrospective study of 146 advanced solid tumor patients treated with ICIs aims to provide a nomogram to predict 1-year (1y) OS integrating body composition (BC) parameters with standard clinicopathological (CP) features. A two-stage approach was implemented: first random survival forest models were trained and tested to evaluate the prognostic value of (a) CP features alone, (b) BC metrics alone or as newly introduced BC scores, and (c) their combination. The best predictive performance (average cumulative AUC of 0.73 in test set) was achieved by combining 12 CP features with the BC score comprising intramuscolar adipose tissue content, visceral fat area index, and the visceral-to-subcutaneous fat area index ratio. Finally, a nomogram was developed with this feature set, offering a tool for personalized risk stratification and treatment planning (mean absolute error in calibration curve of 0.03 and overall AUC of 0.76). Integrating BC parameters with CP features substantially enhances 1y OS prediction in patients receiving ICIs.

Indexed as

Body CompositionNeoplasmsNomogramsAdultAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesBody compositionCancerImmunotherapyMachine learningNomogramOverall survival prediction

Identifiers

PMID41813706
PMCPMC13103393

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.